Sino Biopharm achieves milestone in innovative drug pipeline

Sino Biopharmaceutical (HKEX: 1177) reported its 2024 Annual Report, showcasing significant progress across its financial and operational metrics. Revenue reached RMB28.87 billion, a 10.2% increase year-over-year, driven by innovative products reaching RMB12.06 billion, representing 41.8% of the total revenue. Six innovative products were approved for marketing, including four Category 1 innovative drugs, with the company planning to launch over 30 innovative products by 2027, accounting for over 55% of total revenue. The report details its commitment to responsible operations, setting out specific, measurable targets.